|

Pralatrexate Clinical Trials

4 actively recruiting trials across 3 locations

No change since May 2026

Also known as: 10-propargyl-10-deazaaminopterin, Difolta, Folotyn, Folotyn®, PDX

Pipeline

Phase 3: 2Phase 1/2: 2

Top Sponsors

  • University of Virginia1
  • Fred Hutchinson Cancer Center1
  • Dizal Pharmaceuticals1
  • Corvus Pharmaceuticals, Inc.1

Indications

  • Cancer4
  • Lymphoma, T-Cell2
  • Refractory T-Cell Non-Hodgkin Lymphoma1
  • Recurrent T-Cell Non-Hodgkin Lymphoma1
  • Peripheral T Cell Lymphoma1

Other1 trial

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Phase 3

Duarte, California1 trial

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

City of Hope National Medical Center

Phase 3

Charlottesville, Virginia1 trial

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

University of Virginia

Phase 1/2

Seattle, Washington1 trial

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.